{"id":"W3029830108","doi":"10.1016/j.clgc.2020.05.013","title":"A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Astellas Pharma; Bayer Fund; Parker Institute for Cancer Immunotherapy; Sanofi; Exelixis; Genentech; Valeant Pharmaceuticals International; Merck; Astellas Pharma US; Society for Immunotherapy of Cancer; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Sunitinib; Dasatinib; Prostate cancer; Hazard ratio; Internal medicine; Oncology; Abiraterone acetate; Clinical endpoint; Randomized controlled trial; Androgen deprivation therapy; Urology; Docetaxel; Confidence interval; Cancer; Tyrosine kinase","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004331057,0.0002097395,0.0009001006,0.0001091968,0.00003801729,0.0000116178,0.0001007317,0.00007515295,0.0006481741],"category_scores_gemma":[0.000288645,0.0001394545,0.0001213737,0.0006547881,0.0001641582,0.0001200538,0.00003431267,0.0002255958,0.000003160961],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001152126,"about_ca_system_score_gemma":0.001144708,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002816956,"about_ca_topic_score_gemma":0.0001807882,"domain_scores_codex":[0.9974081,0.0002848809,0.00115333,0.0004084049,0.0004644105,0.0002808992],"domain_scores_gemma":[0.9984649,0.0003377042,0.0003749894,0.0002005215,0.0003087656,0.0003131555],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9302217,0.002879447,0.001815418,0.0004690816,0.0004373665,0.0002208743,0.001022539,0.0001768125,0.04169658,0.000001859336,0.009802399,0.01125589],"study_design_scores_gemma":[0.8900099,0.04993065,0.002021756,0.0009419047,0.0007447884,0.000004448829,0.000910258,0.0008271164,0.05130568,0.00001134742,0.002940437,0.0003517596],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9903813,0.000577254,0.00006678809,0.00367768,0.00009988642,0.003867681,0.001088861,0.00002023977,0.000220328],"genre_scores_gemma":[0.9945616,0.001582168,0.0006289963,0.0003264923,0.0002761435,0.001272568,0.0003996551,0.00003853811,0.0009138192],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0470512,"threshold_uncertainty_score":0.7097052,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1200264725992522,"score_gpt":0.4509374965081492,"score_spread":0.330911023908897,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}